HUE068185T2 - NEK7-kináz inhibitorok - Google Patents
NEK7-kináz inhibitorokInfo
- Publication number
- HUE068185T2 HUE068185T2 HUE21770328A HUE21770328A HUE068185T2 HU E068185 T2 HUE068185 T2 HU E068185T2 HU E21770328 A HUE21770328 A HU E21770328A HU E21770328 A HUE21770328 A HU E21770328A HU E068185 T2 HUE068185 T2 HU E068185T2
- Authority
- HU
- Hungary
- Prior art keywords
- nek7
- kinase
- inhibitors
- nek7 kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022159P | 2020-05-08 | 2020-05-08 | |
| US202163170761P | 2021-04-05 | 2021-04-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE068185T2 true HUE068185T2 (hu) | 2024-12-28 |
Family
ID=77774963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE21770328A HUE068185T2 (hu) | 2020-05-08 | 2021-05-07 | NEK7-kináz inhibitorok |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US11161852B1 (hu) |
| EP (1) | EP4146348B1 (hu) |
| JP (1) | JP2023524597A (hu) |
| KR (1) | KR20230008763A (hu) |
| CN (2) | CN120699028A (hu) |
| AU (1) | AU2021280893A1 (hu) |
| BR (1) | BR112022022669A2 (hu) |
| CA (1) | CA3182276A1 (hu) |
| CO (1) | CO2022017622A2 (hu) |
| DK (1) | DK4146348T3 (hu) |
| ES (1) | ES2991366T3 (hu) |
| FI (1) | FI4146348T3 (hu) |
| HR (1) | HRP20241304T1 (hu) |
| HU (1) | HUE068185T2 (hu) |
| IL (1) | IL297979A (hu) |
| LT (1) | LT4146348T (hu) |
| MX (1) | MX2022013984A (hu) |
| PH (1) | PH12022553024A1 (hu) |
| PL (1) | PL4146348T3 (hu) |
| PT (1) | PT4146348T (hu) |
| RS (1) | RS65962B1 (hu) |
| SI (1) | SI4146348T1 (hu) |
| TW (1) | TW202208356A (hu) |
| WO (1) | WO2021242505A1 (hu) |
| ZA (1) | ZA202212146B (hu) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4146348T (pt) * | 2020-05-08 | 2024-10-04 | Halia Therapeutics Inc | Inibidores da quinase nek7 |
| CN114751874B (zh) * | 2022-05-30 | 2025-01-24 | 江南大学 | 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用 |
| TW202416965A (zh) * | 2022-08-29 | 2024-05-01 | 日商日本煙草產業股份有限公司 | 吡唑并嘧啶化合物及其醫藥用途 |
| US20240158394A1 (en) * | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| AU2024282230A1 (en) * | 2023-05-26 | 2025-12-04 | Halia Therapeutics, Inc. | Polymorphs of nek 7 inhibitors |
| WO2025010421A1 (en) * | 2023-07-06 | 2025-01-09 | Halia Therapeutics, Inc. | Pharmaceutical compositions for inhibitors of nek7 kinase |
| WO2025067411A1 (zh) * | 2023-09-28 | 2025-04-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2025140570A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
| WO2025160453A1 (en) * | 2024-01-25 | 2025-07-31 | Halia Therapeutics, Inc. | Heterocyclic compounds, such as ht-6184, for use in the treatment of pain |
| WO2025190317A1 (en) * | 2024-03-13 | 2025-09-18 | National Institute Of Biological Sciences, Beijing | Urea compounds as nlrp3 agonists |
| CN118812538A (zh) * | 2024-06-18 | 2024-10-22 | 南京健康产业研究院 | 一种具有抗肾癌活性的化合物及其制备方法与应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| TWI263640B (en) | 2001-12-19 | 2006-10-11 | Bristol Myers Squibb Co | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
| GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| US20050171172A1 (en) | 2003-11-13 | 2005-08-04 | Ambit Biosciences Corporation | Amide derivatives as PDGFR modulators |
| BRPI0608252A2 (pt) | 2005-03-10 | 2010-04-06 | Cgi Pharmaceuticals Inc | entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas |
| AU2008282885A1 (en) | 2007-07-31 | 2009-02-05 | Schering Corporation | Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment |
| PT2268623E (pt) | 2008-03-17 | 2015-09-17 | Ambit Biosciences Corp | Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos |
| AP2011005674A0 (en) | 2008-09-25 | 2011-04-30 | Boehringer Ingelheim Int | Sulfonyl compounds which selectively modulate the CB2 receptor. |
| EP2348018A4 (en) | 2008-09-25 | 2012-04-25 | Kyorin Seiyaku Kk | HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE |
| KR20120059558A (ko) | 2009-08-19 | 2012-06-08 | 암비트 바이오사이언시즈 코포레이션 | 바이아릴 화합물 및 이의 사용 방법 |
| EP2557923A4 (en) | 2010-04-16 | 2013-10-23 | Curis Inc | TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| JP2015504889A (ja) | 2012-01-12 | 2015-02-16 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 除草性イソオキサゾロ［５，４−ｂ］ピリジン |
| ES2646019T3 (es) | 2013-05-14 | 2017-12-11 | Nerviano Medical Sciences S.R.L. | Derivados de 6-amino-7-deaza-purina, proceso para su preparación y su uso como inhibidores de cinasa |
| AU2014278231B2 (en) | 2013-06-11 | 2017-05-25 | KALA BIO, Inc. | Urea derivatives and uses thereof |
| CA2916543C (en) | 2013-06-28 | 2023-03-14 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| US9290519B2 (en) | 2013-11-15 | 2016-03-22 | Exxonmobil Chemical Patents Inc. | Pyridyldiamido transition metal complexes, production and use thereof |
| CA2967125C (en) | 2014-11-14 | 2022-10-25 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
| WO2016138473A1 (en) | 2015-02-26 | 2016-09-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inflammasome activation in myelodysplastic syndromes |
| EP3287463A4 (en) | 2015-04-24 | 2018-07-11 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
| WO2017060874A1 (en) | 2015-10-09 | 2017-04-13 | Abbvie S.Á.R.L | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use |
| WO2017125530A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
| CN107176951A (zh) | 2016-03-11 | 2017-09-19 | 恩瑞生物医药科技（上海）有限公司 | 一种脲类化合物、其制备方法及其医药用途 |
| US10167703B2 (en) | 2016-03-31 | 2019-01-01 | Saudi Arabian Oil Company | Optimal well placement under constraints |
| AU2017279878B9 (en) | 2016-06-21 | 2021-04-29 | Nerviano Medical Sciences S.R.L. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
| AU2017300123A1 (en) | 2016-07-20 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as PERK inhibitors |
| EP3296297A1 (en) | 2016-09-15 | 2018-03-21 | Centre National De La Recherche Scientifique | Benzimidazol derivatives for treating filovirus infection |
| EA201992584A1 (ru) | 2017-05-26 | 2020-06-18 | Икнос Сайенсиз Са | Новые ингибиторы map4k1 |
| EP3638669A1 (en) | 2017-06-13 | 2020-04-22 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| US20200246347A1 (en) | 2017-06-13 | 2020-08-06 | Bayer Pharma Aktiengesellschaft | Substituted Pyrrolopyridine-Derivatives |
| RU2020115098A (ru) | 2017-11-09 | 2021-12-10 | Инфлазоум Лимитед | Соединения новых сульфонамидкарбоксамидов |
| CN112040953A (zh) | 2018-03-09 | 2020-12-04 | 布赖汉姆妇女医院 | 用于心血管疾病的组合治疗 |
| MX2020009234A (es) | 2018-04-05 | 2020-10-12 | Merck Patent Gmbh | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. |
| WO2020010118A1 (en) | 2018-07-03 | 2020-01-09 | Novartis Inflammasome Research, Inc. | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist |
| WO2020035495A1 (en) | 2018-08-14 | 2020-02-20 | Cynora Gmbh | Organic molecules for optoelectronic devices |
| KR20210071976A (ko) | 2018-09-04 | 2021-06-16 | 마젠타 테라퓨틱스 인코포레이티드 | 아릴 하이드로카본 수용체 길항제 및 사용 방법 |
| GB201815045D0 (en) | 2018-09-14 | 2018-10-31 | Univ Ulster | Bispecific antibody targeting IL-1R1 and NLPR3 |
| US11414431B2 (en) | 2018-10-15 | 2022-08-16 | Nimbus Lakshmi, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors |
| JP7443361B2 (ja) | 2018-12-03 | 2024-03-05 | 珠海岐微生物科技有限公司 | 加齢黄斑変性症の治療方法 |
| CA3124970A1 (en) | 2018-12-28 | 2020-07-02 | Cedars-Sinai Medical Center | Methods of treating inflammatory bowel diseases that target ripk2 |
| US20220088144A1 (en) | 2019-01-11 | 2022-03-24 | Universitätsspital Basel | Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery |
| WO2020157126A1 (en) | 2019-01-29 | 2020-08-06 | Università degli Studi di Salerno | Modulators of potassium ion channels and uses thereof |
| CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| US11559536B2 (en) | 2019-05-20 | 2023-01-24 | Duke University | Compositions and methods for the treatment of inflammation in urological pathology |
| MX2022002446A (es) | 2019-08-29 | 2022-06-02 | Hibercell Inc | Compuestos de pirrolopirimidina inhibidores de perk. |
| BR112022005674A2 (pt) | 2019-09-26 | 2022-06-21 | Shenzhen Targetrx Inc | Derivado de anel fundido aromático substituído e composição compreendendo o mesmo, e uso do mesmo |
| US20230140941A1 (en) | 2020-03-13 | 2023-05-11 | University Of Maryland, Baltimore | Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors |
| AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| US20230172941A1 (en) | 2020-03-20 | 2023-06-08 | The Johns Hopkins University | Prophylaxis and treatment of pathogenic coronavirus infections |
| PT4146348T (pt) * | 2020-05-08 | 2024-10-04 | Halia Therapeutics Inc | Inibidores da quinase nek7 |
| US20230210853A1 (en) | 2020-05-08 | 2023-07-06 | Halia Therapeutics, Inc. | Targeted nek7 inhibition for modulation of the nlrp3 inflammasome |
| JP2023528637A (ja) | 2020-06-02 | 2023-07-05 | 成都康弘▲葯▼▲業▼集▲團▼股▲フン▼有限公司 | 新規甲状腺ホルモンβ受容体アゴニスト |
| WO2021252488A1 (en) | 2020-06-08 | 2021-12-16 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| GB202010464D0 (en) | 2020-07-08 | 2020-08-19 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| WO2022086986A1 (en) | 2020-10-21 | 2022-04-28 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| WO2022159835A1 (en) | 2021-01-25 | 2022-07-28 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2022192944A1 (en) | 2021-03-15 | 2022-09-22 | Genieus Genomics Pty Ltd | Combination therapy for treatment of als |
| IL307258A (en) | 2021-04-05 | 2023-11-01 | Halia Therapeutics Inc | NEK7 inhibitors |
| US20220380378A1 (en) | 2021-04-22 | 2022-12-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| EP4330228A4 (en) | 2021-04-26 | 2025-03-26 | The Regents of the University of California | G-ALPHA-S INHIBITORS AND USES THEREOF |
| US20240287081A1 (en) | 2021-06-09 | 2024-08-29 | Icahn School Of Medicine At Mount Sinai | Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof |
| CN115616216B (zh) | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| EP4373489A1 (en) | 2021-07-23 | 2024-05-29 | Novartis AG | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| WO2023125935A1 (zh) | 2021-12-31 | 2023-07-06 | 上海翰森生物医药科技有限公司 | 苯并哌啶衍生物调节剂、其制备方法和应用 |
-
2021
- 2021-05-07 PT PT217703289T patent/PT4146348T/pt unknown
- 2021-05-07 SI SI202130195T patent/SI4146348T1/sl unknown
- 2021-05-07 KR KR1020227041803A patent/KR20230008763A/ko active Pending
- 2021-05-07 FI FIEP21770328.9T patent/FI4146348T3/fi active
- 2021-05-07 CN CN202510888448.XA patent/CN120699028A/zh active Pending
- 2021-05-07 ES ES21770328T patent/ES2991366T3/es active Active
- 2021-05-07 US US17/315,209 patent/US11161852B1/en active Active
- 2021-05-07 PH PH1/2022/553024A patent/PH12022553024A1/en unknown
- 2021-05-07 WO PCT/US2021/031394 patent/WO2021242505A1/en not_active Ceased
- 2021-05-07 TW TW110116590A patent/TW202208356A/zh unknown
- 2021-05-07 JP JP2022567839A patent/JP2023524597A/ja active Pending
- 2021-05-07 HR HRP20241304TT patent/HRP20241304T1/hr unknown
- 2021-05-07 LT LTEPPCT/US2021/031394T patent/LT4146348T/lt unknown
- 2021-05-07 MX MX2022013984A patent/MX2022013984A/es unknown
- 2021-05-07 HU HUE21770328A patent/HUE068185T2/hu unknown
- 2021-05-07 BR BR112022022669A patent/BR112022022669A2/pt unknown
- 2021-05-07 PL PL21770328.9T patent/PL4146348T3/pl unknown
- 2021-05-07 AU AU2021280893A patent/AU2021280893A1/en active Pending
- 2021-05-07 RS RS20241030A patent/RS65962B1/sr unknown
- 2021-05-07 EP EP21770328.9A patent/EP4146348B1/en active Active
- 2021-05-07 CN CN202180048858.3A patent/CN115843272B/zh active Active
- 2021-05-07 IL IL297979A patent/IL297979A/en unknown
- 2021-05-07 CA CA3182276A patent/CA3182276A1/en active Pending
- 2021-05-07 DK DK21770328.9T patent/DK4146348T3/da active
- 2021-09-14 US US17/475,220 patent/US11713321B2/en active Active
-
2022
- 2022-11-07 ZA ZA2022/12146A patent/ZA202212146B/en unknown
- 2022-12-06 CO CONC2022/0017622A patent/CO2022017622A2/es unknown
-
2023
- 2023-05-23 US US18/322,380 patent/US12091413B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023524597A (ja) | 2023-06-12 |
| HRP20241304T1 (hr) | 2024-12-06 |
| ZA202212146B (en) | 2025-06-25 |
| PT4146348T (pt) | 2024-10-04 |
| US11161852B1 (en) | 2021-11-02 |
| LT4146348T (lt) | 2024-10-10 |
| FI4146348T3 (fi) | 2024-09-25 |
| PH12022553024A1 (en) | 2024-05-20 |
| PL4146348T3 (pl) | 2024-11-12 |
| RS65962B1 (sr) | 2024-10-31 |
| IL297979A (en) | 2023-01-01 |
| US20220064173A1 (en) | 2022-03-03 |
| CN115843272B (zh) | 2025-07-18 |
| BR112022022669A2 (pt) | 2023-01-17 |
| CA3182276A1 (en) | 2021-12-02 |
| US11713321B2 (en) | 2023-08-01 |
| EP4146348B1 (en) | 2024-07-03 |
| MX2022013984A (es) | 2023-01-30 |
| US12091413B2 (en) | 2024-09-17 |
| CN115843272A (zh) | 2023-03-24 |
| TW202208356A (zh) | 2022-03-01 |
| AU2021280893A1 (en) | 2023-01-05 |
| WO2021242505A1 (en) | 2021-12-02 |
| CN120699028A (zh) | 2025-09-26 |
| US20210355130A1 (en) | 2021-11-18 |
| SI4146348T1 (sl) | 2024-11-29 |
| US20230416259A1 (en) | 2023-12-28 |
| KR20230008763A (ko) | 2023-01-16 |
| CO2022017622A2 (es) | 2022-12-20 |
| DK4146348T3 (da) | 2024-09-30 |
| ES2991366T3 (es) | 2024-12-03 |
| EP4146348A1 (en) | 2023-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202212146B (en) | Inhibitors of nek7 kinase | |
| IL308193A (en) | RAS inhibitors | |
| GB202001344D0 (en) | Ras Inhibitors | |
| IL320739A (en) | rock2 inhibitors | |
| GB2594788B (en) | Antagonist of PCSK9 | |
| IL288387A (en) | Small molecule inhibitors of nf-kb factor kinase | |
| IL313548A (en) | MET kinase inhibitors | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| IL314049A (en) | PARP7 inhibitors | |
| IL316616A (en) | ROCK2 inhibitors | |
| LT4192814T (lt) | Transgliutaminazės inhibitoriai | |
| SG10201909596RA (en) | Synthesis of Tyrosine Kinase Inhibitors | |
| HUE069300T2 (hu) | Transzglutaminázok inhibitorai | |
| HUE068818T2 (hu) | Transzglutamináz inhibitorok | |
| IL308513A (en) | ALK2 kinase inhibitors containing imidazoles | |
| TWI908811B (zh) | Nek7激酶抑制劑 | |
| HK40088585A (en) | Inhibitors of nek7 kinase | |
| GB202107612D0 (en) | Inhibitors of metallo-beta-lactamases | |
| GB202203181D0 (en) | Inhibitors of elF4A | |
| PT4192812T (pt) | Inibidores de transglutaminases | |
| HK40118888A (en) | Inhibitors of met kinase | |
| GB202113104D0 (en) | Antagonist of pcsk9 | |
| GB202020553D0 (en) | Antagonist of pcsk9 | |
| GB202013998D0 (en) | Antagonist of pcsk9 | |
| GB202003756D0 (en) | Antagonist of PCSK9 |